Possible article: Taclonex: A Topical Treatment for Psoriasis Psoriasis is a chronic autoimmune disorder that affects the skin and nails, causing redness, scaling, itching, and pain. The exact cause of psoriasis is unknown, but it is believed to be related to genetic, environmental, and immune factors that trigger abnormal growth and inflammation of skin cells. Psoriasis affects about 2% of the global population, and can occur at any age, but typically appears between 15 and 35 years of age. There are many types of psoriasis, and the severity and location of the lesions can vary widely. There is no cure for psoriasis, but there are many treatments that can help to alleviate symptoms and improve quality of life. One of the most effective and widely used topical treatments for psoriasis isTaclonex. Taclonex is a combination of two active ingredients, calcipotriene and betamethasone dipropionate, that work together to reduce inflammation and suppress abnormal skin cell growth. Calcipotriene is a synthetic form of vitamin D that can regulate the proliferation and differentiation of skin cells, and also has immunomodulatory, anti-inflammatory, and antiproliferative effects. Betamethasone dipropionate is a potent corticosteroid that can reduce itching, redness, and inflammation by inhibiting the release of cytokines and other inflammatory mediators. Together, calcipotriene and betamethasone dipropionate can improve the symptoms of psoriasis by decreasing the thickness, scaling, and erythema of the plaques, and by increasing the skin's resistance to further damage. Taclonex is available as a topical suspension or ointment, and is applied once daily to the affected area(s) of the skin or scalp. The dosage and duration of treatment may vary depending on the severity and location of the psoriasis, and the response of the individual patient. Taclonex should not be used on the face, groin, or underarms, as these areas are more sensitive and may absorb more of the medication, leading to possible side effects. Taclonex may also interact with some other medications, such as oral corticosteroids, cyclosporine, or thiazide diuretics, and should be used with caution in patients with liver or kidney disease, diabetes, or impaired calcium metabolism. Taclonex is most effective in patients with moderate to severe plaque psoriasis, who have not responded well to other topical therapies, or who cannot tolerate systemic or phototherapy. Taclonex can provide rapid and long-lasting relief of symptoms, and can also help to prevent relapses. However, Taclonex may cause some side effects, such as itching, burning, stinging, dryness, or irritation of the skin, especially in the first few days or weeks of treatment. These side effects may be more severe in elderly or pediatric patients, or in patients with skin infections or open wounds. Taclonex may also increase the risk of adrenal suppression or hypothalamic-pituitary-axis suppression, which can affect the immune and hormonal systems. Taclonex is available only by prescription, and may not be covered by all insurance plans. Taclonex is also quite expensive, with a retail price of about $600 for a 60-gram tube of 0.005%/0.064% suspension. There are some generic options available that may be less costly, but they may not have the same quality or efficacy as the brand-name Taclonex. It is important to consult with a healthcare provider or a pharmacist before starting or stopping any medication, and to follow the prescribing instructions carefully. Taclonex is a valuable and safe treatment for psoriasis, but it should be used with caution and under close medical supervision. References: National Psoriasis Foundation. (2021). About Psoriasis. Retrieved from https://www.psoriasis.org/about-psoriasis. Taclonex. Prescribing Information. Leo Pharma Inc. (2018). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021902s019lbl.pdf. Wiegand, S., Wetzig, T., Limbert, G., & Blank, U. (2001). The rationale behind topical use of vitamin D analogues and corticosteroids for psoriasis. International Journal of Dermatology, 40(5), 319-326. doi: 10.1046/j.1365-4362.2001.01198.x.